The previous earnings report from Verastem (VSTM) was filled with volatility and surprises. As I outlined in my last piece, Verastem's Earnings - Is It a Buy Now?, Verastem is a company filled with … [Read more...] about Another Quarter of Growth for Verastem…Is It Enough?
Whether you use Yahoo Message Board, SeekingAlpha, or StockTwits, these forums have similar benefits and drawbacks. First, they allow for the transfer, discussion, and debates on thoughts and data … [Read more...] about How to Approach Investor Forums
As discussed in part one of this two part series, both Verastem and AVEO appear to be going to the ASCO conference this weekend with minimal updates pertaining to their pipeline. With volatility and a … [Read more...] about Lackluster ASCO Results for Verastem and AVEO – Part 2
Given Verastem's (VSTM) depressing price movement since reaching $10 in 2018 and AVEO's volatile start to 2019, neither company has brought forth any interesting data for presentation at ASCO 2019. … [Read more...] about Lackluster ASCO for Verastem and AVEO
Verastem (VSTM) reported earnings on May 9th after the close of the American market and proceeded to plunge 28% during Friday's trading session. What was the cause of this selloff? Here are three big … [Read more...] about Verastem’s Earnings: Is It a Buy Now?
Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
Last fall, Verastem Oncology (NASDAQ: VSTM) received FDA-approval for its first drug, Copiktra, an oral monotherapy for the treatment of relapsed or refractory chronic lymphotic leukemia, small … [Read more...] about Verastem Oncology: Looking for a Port in the Storm
Lymphoma Patients Want and Need A Better Quality Of Life As a Lymphoma survivor, I can say unequivocally, that TO MUCH TIME is spent in the chemo wing, away from our families. Therefore, as … [Read more...] about (Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Good Morning! We hope you all are enjoying your early morning trading! Today, three companies we … [Read more...] about Morning Update-Form 13G’s On Deck!
Leave a comment and click here to subscribe for MS article alerts and our newsletter! Overview January 10th, in an Amended 13G/A, Street Corp updated their reported holdings in VSTM to … [Read more...] about State Street Corp’s Amended 13G/A Reveals 11.53% Ownership of VSTM